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a b s t r a c t
Vitamin D deficiency (VDD) is highly prevalent worldwide, with adverse effects on bone health but also
potentially other unfavorable consequences. VDD and asthma-incidence/severity share many common
risk factors, including winter season, industrialization, poor diet, obesity, dark skin pigmentation, and
high latitude. Multiple anatomical areas relevant to asthma contain both the enzyme responsible for
producing activated vitamin D and the vitamin D receptor suggesting that activated vitamin D (1,25-
dihydroxyvitamin D) may have important local effects at these sites.
Emerging evidence suggests that VDD is associated with increased airway hyperresponsiveness,
decreased pulmonary function, worse asthma control, and possibly decreased response to standard anti-
asthma therapy. However the effect is inconsistent with preliminary evidence from different studies
suggesting vitamin D is both beneficial and detrimental to asthma genesis and severity.
Current evidence suggests that supplementation with moderate doses of vitamin D may be appro-
priate for maintenance of bone health in asthmatics, particularly steroid users. However emerging data
from an increasing number of randomized, controlled, intervention studies of vitamin D supplementa-
tion in pediatric and adult asthma are becoming available and should help determine the importance, if
any of vitamin D for asthma pathogenesis.
The purpose of this second of a two-part review is to review the current human literature on vitamin D
and asthma, discussing the possible consequences of VDD for asthma and the potential for vitamin D
repletion as adjunct therapy.
© 2015 Elsevier Ltd. All rights reserved.
1. Introduction
Much human research on vitamin D and asthmatic disease is
now available. This second part of a two-part review will briefly
introduce vitamin D and its sources. However, the main focus will
be human evidence linking vitamin D to human asthma, including
epidemiological, case-control, cross-sectional, prospective and
intervention studies. We will discuss the merits and limitations of
each study design regarding asthma and vitamin D. However,
unanswered questions remain. We have reviewed mechanisms by
which vitamin Dmay influence asthmatic disease in part one of this
two-part review [92]. Therefore, we will conclude this review with
some recommendations for future research in the area.
There are two major forms of fat-soluble vitamin D: vitamin D2
(ergocalciferol) available from plant sources such as ultraviolet-B
(UV-B) irradiated mushrooms and vitamin D3 (cholecalciferol)
available from animal sources such as oily fish and produced in
human skin upon exposure to ultraviolet B radiation (UV-B).
Although both forms of vitamin D are bioactive and available as a
dietary supplement, it is recognized that vitamin D3 is more potent
[159].
Systemic vitamin D status is reliably indicated by the serum
level of 25-hydroxyvitamin D (25(OH)D) [70,75,78], which reflects
cutaneous photosynthesis and oral intake from both diet and
supplements. Currently, there is no consensus on optimal levels of
25(OH)D. The 2010 Institute of Medicines (IOM) recommended that
vitamin D deficiency (VDD) be defined as a 25(OH)D level
<50 nmol/L, with a level >50 nmol/L representing vitamin D
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sufficiency (VDS) [139]. However, these guidelines have been crit-
icized as being overly conservative by being based almost solely on
studies of bone health [69,167]. Higher 25(OH)D levels (e.g.
>100 nmol/L) have been suggested to be necessary for optimal
immune function and respiratory outcomes [17,76,78,79,166].
For the purposes of this review we will use the most up to date
recommendations from the Endocrine Society [76] e see Table 1.
Despite advances about the importance of vitamin D, VDD is
widespread worldwide with recent estimates suggesting 1 billion
people are affected worldwide [74].
Although some foods contain vitamin D (mainly oily fish and
fortified products), the major source for most humans is cutaneous
photosynthesis under the influence of UV-B radiation from sun-
shine [74]. Therefore, VDD e like asthma e is more common in
polluted, industrialized regions [115], at high latitude [87] and in
winter season [49]. Similar to asthma, body size and adiposity [51],
as well as darker skin pigmentation [38], exposure to cigarette
smoke [10,73,123,153], pollution [9,89] and physical inactivity
[73,145,163] are associated with decreased vitamin D status. Other
determinants of vitamin D status include clothing and sunblock use
[116], inadequate diet and supplement usage as well as genetic
variation [179].
It is notable that the environmental changes attributable to the
increase in asthma incidence and severity also cause VDD. The
recent emergence of widespread VDD appears related to sun
avoidance and seems to parallel the increased incidence of multiple
diseases, including asthma.
2. Methods
References were identified by searches of MEDLINE, CINAHL,
EMBASE and online Cochrane databases through January 2015.
Keywords used included vitamin D and asthma, wheezing, airway
inflammation, airway smooth muscle, and respiratory infection.
Only manuscripts published in English are included. Articles were
chosen according to their relevance for this review and their bib-
liographies were also searched for further references.
3. Results and discussion
3.1. Evidence linking vitamin D to asthma
There are two opposing theories regarding the effect of
increasing 25(OH)D status in asthma. We will consider both
Abbreviations list
% predicated FEV1 percent predicated based on normative
values for healthy age and BMI matched
subjects.
1,25D 1,25-dihydroxyvitamin D
25(OH)D 25-hydroxyvitamin D
AAR allergic rhinitis þ allergic asthma
ACQ asthma control questionnaire
ACT asthma control test
AD atopic dermatitis
AR allergic rhinitis
ASM airway smooth muscle
ATAQ asthma therapy assessment questionnaire
BALF bronchoalveolar lavage fluid
BMI body mass index
d day
DB double-blind
DBRCT double-blind, randomized, placebo controlled trial
ED emergency department
eNO exhaled nitric oxide
FeNO fraction of exhaled nitric oxide
FEV1 forced expiratory volume in 1 s
FIV1 forced inspiratory volume in 1 s
FoxP3 forkhead box P3
FVC forced vital capacity
GCS glucocorticoids
GINA global initiative for asthma
hs-CRP high sensitivity C reactive protein
ICS inhaled corticosteroid
IFN g interferon gamma
IgE immunoglobulin E
IL interleukin
IM intramuscularly
IOM Institute of Medicines
ISAAC International Study of Asthma and Allergies in
Childhood
IU international unit
LABA long-acting b-agonist
LL-37 the protein precursor to hCAP-18 which undergoes
extracellular cleavage to generate a 37-residue active
cationic peptide
NHANES National Health and Nutrition examination survey
OCS oral corticosteroid
OGG-1 8-Oxoguanine-DNA glycosylase;
OR odds ratio
PC20-FEV1 provocation dose of methacholine require to induce a
20% drop in FEV1
PEFR peak expiratory flow rate
RCT randomized controlled trial
ROS reactive oxygen species
RTI respiratory tract infection
RXRa retinoid X receptor-a
SCIT subcutaneous immunotherapy
SIT specific immunotherapy
SOD superoxide dismutases e enzymes which catalyze the
dismutation of the superoxide radical
SR steroid resistant
T-reg cells regulatory T cells
TGF transforming growth factor
Th t helper
UV-B ultraviolet-B radiation
VDBP vitamin D binding protein
VDD vitamin D deficiency
VDI vitamin D insufficiency
VDR vitamin D receptor
VDRE vitamin D response element
VDS vitamin D sufficiency
VDT vitamin D toxicity
Table 1
Definitions of vitamin D status based on serum 25(OH)D level [76].
Definition Abbreviation Serum 25(OH)D level
Vitamin D deficiency VDD 50 nmol/L
Vitamin D insufficiency VDI 50e75 nmol/L
Vitamin D sufficiency VDS 75e250 nmol/L
Vitamin D toxicity VDT >375 nmol/L
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theories and present existing cross sectional and interventional
evidence.
3.1.1. Is vitamin D detrimental in asthma?
Wjst and Dold first hypothesized that the introduction of
vitamin D fortified foods was related to the asthma and allergy
epidemic, suggesting that if protective antigen-reactive Th1
memory cells fail to develop, the subsequent predominance of Th2
cells can trigger allergic reactions [180]. This initial hypothesis was
based on the observation that the introduction of vitamin D food
fortification and specific vitamin D supplementation strategies
seems to mirror the emergence of an asthma epidemic [175e178].
However, there is little evidence that 25(OH)D levels increased
during this period and it is likely that several factors may even
decreased 25(OH)D levels, including increased indoor time (i.e.
indoor occupations and recreation) and increased sunscreen use.
However, some animal work has seemingly supported the view
that vitamin D is detrimental in asthma. VDR knockout mice do not
develop airway inflammation or experimental asthma [174]. The
same group went on to demonstrate that VDR expression is
mandatory for the induction of lung inflammation [173]. Together
these animal reports suggest that vitamin D and the VDR are
important regulators of lung inflammation.
This initial hypothesis and animal model evidence was sup-
ported by limited human evidence. The first human report of
potentially increased risk of atopy with vitamin D supplementation
came in 1993. Peanut oil used for the pharmacological preparation
of vitamin D to prevent peanut sensitization was associated with a
markedly increased risk of allergen sensitization (OR ¼ 9.0;
p < 0:003) compared to the supplement without allergen [44].
Later trials of supplementation with peanut oil or water with dis-
solved vitamin D alone or in combination with vitamin A demon-
strated increased adverse allergic outcomes, including asthma
[45,97,98]. The preparations used contained a combination of
peanut oil as well as vitamins A and D, and therefore it is difficult to
speculate on the individual contribution of each component. These
early reports are supported by several prospective studies sug-
gesting that early vitamin D supplementation may increase the risk
of allergic disease among healthy infants [8,59,82,130,164] and that
vitamin Dmay have detrimental effects on childhood lung function
[42] and atopic disease [71,181].
However, the effect of vitamin D on immune and inflammatory
signals may outweigh any potential shifting of Th1eTh2 balance
and the majority of existing mechanistic [92] as well as observa-
tional data suggest that vitamin D repletion may be therapeutic in
asthma. In fact, some authors have suggested that VDD may be
responsible for the increase in allergic diseases and asthma prev-
alence worldwide [171,107,106]. However, interventional data has
proved inconsistent (see below).
3.1.2. Epidemiologic data
There is decreased opportunity for vitamin D skin photosyn-
thesis at higher latitude [74]. Therefore if vitamin D is truly
important in asthmatic disease we can expect higher asthma inci-
dence at higher latitude. Indeed, several reports have suggested
that latitude is positively correlated to asthma [2,56,87,95] and al-
lergy [80]. However, not all ecological studies demonstrate this
effect, with some studies noting no interaction [81,114], and others
still an increased risk at lower latitude [131,151,170,176,187]. It
should be noted that geographical latitude can only ever serve as a
proxy for vitamin D status. Many factors affect asthma prevalence
and may also vary by region, including healthcare resources, local
population, genetics and pollution. Additionally, many factors affect
the prevalence of VDD and may also vary by region and latitude,
including diet and supplement use, religious clothing and sun
habits. Indeed, VDD has been reported to common in low latitude
countries with abundant sunshine [124,52].
Ethnic groups with darker skin have higher prevalence and
severity of asthma when compared to those with lighter skin
pigmentation residing in similar locations [57,62,65,119]. Although,
many factors could contribute to this observation (e.g. dietary
habits, healthcare access), it is noteworthy that those with darker
skin pigmentation have the same capacity but significantly
decreased efficiency of cutaneous vitamin D photosynthesis upon
exposure to UV-B [38]. Therefore, heavily pigmented individuals
will typically have lower 25(OH)D status compared to lighter pig-
mented individuals residing at similar latitudes [68,72].
Nevertheless, a randomized trial of Norwegian children with
atopic eczema demonstrated significant improvements after 4
weeks in a sunny climate [26]. Further, an observational study in
2007 of Spanish asthmatic children revealed that health related
quality of life was highest in summer and lowest in autumn [60].
Indeed, sunny hours have been inversely associated with asthma
prevalence [5]. Additionally, a subsequent longitudinal cohort study
of 415 Australian children followed from birth to age 16, demon-
strated that reported summer sun exposure was associated with
reduced eczema and rhinitis but not inhalant allergen sensitization
or asthma risk [90]. However, other studies note an increased risk of
asthma and allergic diseasewith higher UV-B exposure [131]. These
discrepancies can potentially be explained by recent trends in
lifestyle e.g. sunscreen use and increased time spent indoors, which
would decrease vitamin D photosynthesis. Considering that UV-B
radiation is the major source of vitamin D for most populations,
these observations appear to support a role for vitamin D in asthma.
Epidemiologic data demonstrate a positive association between
25(OH)D level and pulmonary function in healthy children
[184,185], adults [19,37,158], elderly males but not females [165],
asthmatics [154], smokers [101] and those with COPD [86]. A
detailed retrospective analysis from the UK demonstrated a linear
association between 25(OH)D and lung function including both
forced expiratory volume in 1 s (FEV1) and forced vital capacity
(FVC), which was consistent through the seasons and not fully
explained by infections, adiposity or other lifestyle or socio-
economic measures [16]. A 20 year, Danish, prospective study
with 18,507 subjects demonstrated that lower plasma 25(OH)D
levels were associated with both lower lung function and faster
decline in lung function (both FVC& FEV1) [1]. Additionally, a cross-
sectional analysis of 650 mainly black, smokers revealed that there
was no relationship between 25(OH)D and cathelicidin levels, but
that lung function decrements were associated with low cath-
elicidin and were greatest among individuals with lower 25(OH)D
levels [99].
Supporting the idea that vitamin D is important in asthmatic
and atopic disease, inverse associations between 25(OH)D and al-
lergy [58,83,148] as well as asthma [107,58,88] have also been re-
ported. However, other reports suggest that dietary vitamin D [127]
and serum 25(OH)D concentrations [147] were not related to FEV1
and that risk for atopic disease, including allergic rhinitis [181] and
eczema [71] was higher with increased 25(OH)D. Taken together,
most but not all existing epidemiological reports suggest that
25(OH)D may be an important and modifiable variable in the
maintenance of lung health.
3.1.3. Case-control studies of vitamin D status and asthma
25 case control studies totaling 2568 asthmatic cases and 4376
controls have examined vitamin D intake, status as well as corre-
lations with respiratory/atopic parameters in asthma cases
compared to controls (see Table 2).
The case-control study by Carraro et al. deserves attention. The
authors conducted a comprehensive observational study
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Table 2
Case control studies of vitamin D status and asthma.
Population Age (years) Location Latitude Main findings Reference
80 adult asthmatics & 80 age & sex-
matched controls.
18e50 Aberdeen, Scotland
& Norfolk England
52e57!N No significant differences in energy-
adjusted vitamin D intake or 25(OH)D
between cases & controls. All subjects were
VDD.
[48]
85 African-American, childhood
asthmatics & 21 healthy controls.
6e20 Washington DC, USA 39! N VDD & VDI significantly greater in cases
than controls.
[57]
50 childhood asthmatics & 50 healthy
controls.
6e18 Shiraz, Iran 30! N 25(OH)D was significantly lower in cases
than controls and positively correlated with
FEV1 and FEV1/FVC. No correlation with
eosinophil counts, asthma duration,
number of hospitalization or unscheduled
visits in the previous year.
[3]
45 asthmatic children & 59 healthy
controls.
9e11 Verona, Italy 45! N No significant difference in 25(OH)D
between cases and controls. 25(OH)D
positively correlated with FVC and FEV1 but
negatively with exercise induced
bronchoconstriction.
[35,36]
483 asthmatic children & 483 age,
gender& ethnicity matched controls.
<15 Doha, Qatar 25! N 25(OH)D levels were significantly lower
and IgE significantly higher in cases than
controls with a negative correlation
evident. Cases had less exposure to
sunshine and lower exercise. VDD was the
strongest predictor of asthma in this
population.
[53] and [15]
36 children with SR asthma, 26 with
moderate asthma, and 24 healthy
controls.
6e16 London, England 52! N 25(OH)D levels were significantly lower in
SR asthma than either mild asthmatics or
controls and inversely correlated with ASM
mass, bronchodilator response and IgE but
positively correlated with asthma control,
FEV1 and FVC. Further low 25(OH)D was
correlated with asthma exacerbation and
medication usage.
[66]
287 asthmatic children & 273 healthy
children.
6e14 San Juan, Puerto Rico 18! N No significant difference in 25(OH)D
between cases and controls. Lower 25(OH)D
correlated with severe asthma
exacerbation, atopy, and a lower FEV1/FVC
in cases.
[22]
103 asthmatics & 102 healthy control
subjects.
8.5e46 Denver, Colorado 39! N VDD was evident in 47.6% of patients and
56.8% of controls. In multivariate regression
models, 25(OH)D correlated positively with
expression of vitamin D regulated genes,
but was only significant in children. An
inverse correlation between 25(OH)D and
serum IgE levels was observed but only in
children. 25(OH)D was significantly
inversely correlated with ICS dose, again
only in children.
[63]
15 children with SR asthma, 7 with
moderate asthma,& 6 non-asthmatic
controls.
6e16 London, England 52! N Children with SR asthma had significantly
higher levels of VDBP in BALF but not in
serum compared with moderate asthmatics
and controls. VDBP concentration in BALF
correlated negatively with asthma control
and %FEV1 but positively with ICS usage.
[67]
39 children with controlled asthma and
30 age- and sex-matched controls.
6e16 El Manar, Tunisia 37! N VDD was higher in asthma compared to
control, VDS was lower in asthma than
control. Th1/Th2 ratio and CD25(þ)
Foxp3(þ) T-reg cells were positively related
to 25(OH) D level while IL-17 was
negatively correlated.
[109]
Of 25,616 Norwegian adults who
participated in 2 health surveys
1995-1997 and 2006-2008, a nested
case-control study included 584
new-onset asthma cases and 1958
non-asthma controls.
19e55 Nord-Trøndelag,
Norway
63! N After adjustment for potential asthma risk
factors, baseline VDD was not significantly
correlated with asthma in either women or
men. Co-existent allergic rhinitis modified
the association in men only.
[110]
263 asthmatic children & 284 healthy
controls.
2e19 Worchester, USA 42! N No significant difference in 25(OH)D
between cases and controls. 25(OH)D did
not relate to asthma severity.
[120]
42 non-severe asthmatic children, 11
with severe asthma and 15 healthy,
non-asthmatic children.
8e17 Padova, Italy 45! N A metabolomic approach to exhaled breath
condensate (breathomics) revealed that the
absence of ercalcitriol, (active metabolite of
vitamin D2) differentiated severe asthma
from both non-severe asthma and healthy
children.
[29]
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regarding the metabolomics of exhaled breath condensate
(breathomics) in severe asthmatic children vs. non-severe asth-
matic children and healthy children. They observed that the
absence of ercalcitriol (an active metabolite of vitamin D2)
differentiated severe asthma from both children with non-severe
asthma and healthy children. This is perhaps the first report of
vitamin D being recovered specifically in the lung. The authors
speculate that children with severe asthma and treated with
high-dose inhaled corticosteroids (ICS) may have insufficient
vitamin D in the airways [29].
Table 2 (continued )
Population Age (years) Location Latitude Main findings Reference
30 infants with recurrent wheezing and
45 healthy, similar aged infants
without any history of acute or
chronic illness
Infants Ankara, Turkey 40! N 25(OH)D was not statistically different
between the groups. However, the sample
size was small, mean 25(OH)D was lower in
cases than controls and VDI was common
(90% of wheezers, 77.8% of controls).
[133]
Prospective cohort study of 20
asthmatics and 19 non-asthmatics
followed for ~1y.
Not reported Minnesota, USA 44! N Overall negative correlation between
25(OH)D and decreased pneumococcal
antibody titers during follow-up, especially
significant among those with asthma and/or
atopy.
[141]
85 asthmatic children & 85 non-
asthmatic children.
2e14 Tekirdag,
Turkey
37! N 25(OH)D was significantly lower in
asthmatic children. There was a negative
correlation between 25(OH)D and ER/
hospital admissions, RTI incidence, asthma
attacks and asthma severity.
[162]
50 asthmatic children & 25 non-
asthmatic children.
1e15 Lucknow, India 29! N VDI was correlated with asthma incidence
and decreased asthma control.
[7]
35 children with AAR, and 11 patients
with AR & 28 healthy controls.
8e13 Palermo, Italy 39! N 25(OH) was highest in controls followed by
AR and then AAR, while plasma IL-31 and
33 were lowest in controls followed by AR
and AAR. Neither plasma IL-31 or IL-33
correlated with 25(OH)D. 25(OH)D
correlated negatively with IgE levels and
total atopy index only in AAR.
[20]
40 wheezy infants; 30 age-and-gender
matched healthy infants.
1e3 Samsun, Turkey 41! N 25(OH)D levels were lower in wheezy
infants vs. controls. There was a negative
relationship between 25(OH)D and IgE
levels.
[46]
120 asthamtic children and 74 age &
gender matched, non asthmatic
controls.
4.4 ± 1.2 Istanbul, Turkey 41!N Mean 25(OH)D level was slightly but not
significantly lower in cases than controls.
Among cases, the total number of
exacerbations, asthma severity and
systemic GCS need in the previous year
were significantly higher in the VDD group.
[50]
69 active asthamics (wheezing in the
past 12 months and ever asthma on
the ISAAC questionnaire) and 671
controls (no hisotry of wheeinzg of
asthma).
16e17 Cyprus 35! N In adjusted models, mean 25(OH)D levels
were significantly lower amongst
asthamtics compared to controls. Within
asthmatics, there was a negative trend
between 25(OH)D and the number of
reported asthma severity indicators.
[93]
68 asthmatics and 77 healthy women. 14e65 North Jordan 32! N The prevalence of low 25(OH)D
(<37.5 nmol/L) was non statistically higher
in asthmatic women compared with
controls. Decreased 25(OH)D correlated
posisitvely with number of asthma
medications, whereas 25(OH)D directly
correlated with ACT and GINA classification.
After adjusting for age, the odds of having
VDD for asthmatic women were 35.9 times
higher than that for control women
[143]
44 asthmatic children and 44 healthy
controls.
5e13 Bangalore, India 32! N 25(OH)D levels were significnatly lower in
asthmatics vs. controls. 25(OH)D was
significantly positively correlated with %
FEV1 and FEV1/FVC%.
[149]
30 children with acute wheeze and 101
age-matched controls with no
history of wheeze or sensitization to
airborne allergens.
0.5e4 Stockholm, Sweden 62! N VDI was correlated with 270% increased risk
of acute wheeze. No correlation between
25(OH) and atopy, presence of virus/
bacteria or recurrent RTI.
[152]
73 wheezing children and 75 controls Not reported Istanbul, Turkey 41! N No significant difference in 25(OH)D
between cases& controls. However, 25(OH)
D was significantly lower in recurrent
wheezers (>3 wheezing attacks) & children
with a positive Asthma Predictive Index.
[162]
Abbreviations: 25(OH)D ¼ 25-hydroxyvitamin D; AAR ¼ allergic rhinitis þ allergic asthma; ACT ¼ asthma control test; AR ¼ allergic rhinitis; BALF ¼ bronchoalveolar lavage
fluid; ER ¼ emergency room; FEV1 ¼ forced expiratory volume in 1 s; FVC ¼ forced vital capacity; GCS ¼ glucocorticoids; GINA ¼ global initiative for asthma; ICS ¼ inhaled
corticosteroid; IgE ¼ immunoglobulin E; IL ¼ interleukin; ISAAC ¼ International Study of Asthma and Allergies in Childhood; RTI ¼ respiratory tract infection; SR ¼ steroid
resistant; T-reg cells ¼ regulatory T cells; VDBP ¼ vitamin D binding protein; VDD ¼ vitamin D deficiency; VDI ¼ vitamin D insufficiency; VDS ¼ vitamin D sufficiency.
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Observational studies, including case-control studies have
several well-known limitations. Choice of controls can determine
the observations and therefore even when efforts to match for
confounding variables are made, the results can be biased. Further,
even those with statistical adjustments, observational studies are
limited by potential confounding. Therefore, it is impossible to
ascertain whether an insufficient 25(OH)D level is responsible for
reduced asthma control or that poor asthma control leads to
decreased 25(OH)D status through acute inflammation as has been
reported post-orthopedic surgery [138,168] or reduced sun expo-
sure due to asthma related inactivity. A recent in vivo study
demonstrated that acute lung inflammation induced by exposure to
house dust mite did not lead to altered 25(OH)D levels [33] sug-
gesting that altered vitamin D status is not caused by allergic
inflammation. However, children with wheezing, shortness of
breath or allergy may avoid sunlight and outdoor activities
[14,15,162] and therefore present with lower 25(OH)D.
Existing case-control studies regarding vitamin D and asthma
have compared asthmatics to healthy controls by assessing mea-
surements which were collected simultaneously and only at a
single time point. Therefore it is not possible to determine temporal
relationships between exposure and outcome. Further, many of
these study populations exhibit widespread VDD and VDI and
therefore it is difficult to comment on the effect of higher 25(OH)D
on asthma parameters.
Importantly, more than being interested in whether vitamin D
intake and 25(OHOD status differs between asthmatic cases and
non-asthmatic controls, the key question is whether vitamin D can
influence asthma pathogenesis, severity and control. Because case-
control studies can not answer these questions, these studies must
be interpreted with caution. Hence, case-control studies are
therefore placed low in the hierarchy of scientific evidence.
3.1.4. Cross-sectional studies of vitamin D status in asthma
Although, vitamin D may be of importance in adult asthma
[105,154], the association of vitamin D deficiency with severity of
asthma is reported to be particularly strong in children [63] e
however this observation is not consistent [88]. Nevertheless,
available cross-sectional data from 36 studies, involving 386,584
subjects suggest that low 25(OH)D is associated with poor control,
increased exacerbation, reduced lung function and, increased
medication usage in asthmatics (Table 3).
These cross-sectional studies suffer from many of the same
limitations as case-control studies. In particular, assessments were
conducted simultaneously and typically only at a single time point
only. Further, the widespread nature of VDD and VDI prevents the
assessment of high 25(OH)D on asthma parameters. Similar to
case-control studies, the results of cross-sectional reports must be
interpreted with caution. Ultimately, these observational studies
provide associations between vitamin D and asthma but can not
determine cause or effect and hence are only a step in under-
standing relationships between vitamin D and respiratory
outcomes.
3.1.5. Prospective studies of vitamin D status and asthma outcomes
In contrast to case-control and cross-sectional studies, pro-
spective studies follow subjects who are similar but differ with
respect to certain factors. These factors can be studied to determine
how they affect certain outcomes. There are 7 post-natal prospec-
tive studies regarding asthma, involving a total of 14,041 subjects
followed for 1e31 years (Table 4).
Compared to observational studies, prospective cohort studies
are superior regarding assessment of sequence between exposure
and outcome. However, the longitudinal design of these studies
means there is a lag between assessment of exposure and
assessment of outcome. Because many factors influence both
asthma pathogenesis and 25(OH)D levels and because 25(OH)D
levels ae known to fluctuate over time, prospective studies too are
limited in this context. Therefore interventional trials are best
suited to study the effects of vitamin D and asthmatic disease.
3.1.6. Interventional data of vitamin D in asthma
Case-control, cross-sectional and prospective studies designs
are interesting and provide insights into any potential relationship
between vitamin D and asthma outcomes. However, intervention
data, particularly from randomized, controlled trials designed to
specifically assess the impact of vitamin D on asthma parameters
provide far more robust information. There are 17 published trials
of vitamin D supplementation in asthma involving 1578 asthmatics
with varying doses and preparations of vitamin D followed for
4e52 weeks (Table 5).
The idea that vitamin D therapy could be therapeutic in asthma
and allergic disease dates back to the early 20th century. Vitamin D
was only discovered around this time. This led to a successful
treatment of rickets and interest in other conditions, including
asthma and allergy. Viosterol (which contained ergosterol, the
precursor to ergocalciferol e vitamin D2) was the vehicle of choice
for these early investigations into asthma.
An early pilot study involving a heterogenous group of 11 sub-
jects with either non-atopic asthma (n ¼ 3), chronic uriticaria
(n¼ 2) or ragweed allergy þ asthma (n¼ 6) treated with very large
doses of viosterol (up to 1,380,000 IU bi-weekly for weeks to
months) reported variable results in the Journal of the American
Medical Association in 1933. In this pilot study, non-atopic asth-
matics and subjects with uriticaria showed little improvement
while subjects with ragweed allergy showed varying but obvious
improvements [137].
These observations led the same investigators to conduct a
subsequent larger study focusing on 212 patients specifically with
asthmatic allergic to ragweed. The treatments were high dose
viosterol (120,000e300,000 IU/day, n ¼ 68) or high dose viosterol
and pollen injection (n ¼ 144). In the viosterol only group, 82.4%
experienced definite significant relief. In the viosterol þ pollen
group, 96.5% had comparable degrees of relief. The authors wrote
that: ‘92% of the entire series were definitely and significantly
relieved’. Interestingly, despite the massive doses of vitamin D2
utilized, hypercalcemia was not evident [136].
These early American studies were followed up by some pub-
lications in small European journals in the mid 20th century
[28,85]. In 1976, a German group reported a double-blind, crossover
trial of oral calcium þ vitamin D2 (undescribed doses) on 12 pa-
tients with allergic bronchial asthma and airway obstruction.
Within 60 min of application, a statistically significant reduction of
airway resistance and intrathoracic gas volume, as well as an in-
crease of FEV1 and forced inspiratory volume in 1 s (FIV1) was
observed compared to placebo. It was concluded that calcium,
given orally in combination with vitamin D2, causes a decrease of
airway obstruction in patients with allergic bronchial asthma [161].
These early trials are limited by the large doses of vitamin D
used, use of vitamin D2 as opposed to vitamin D3, sub-optimal trial
design and missing details. Nevertheless and despite the incon-
sistent beneficial effects observed from these early trials, interest in
the therapeutic potential of vitamin D in asthma seemed to
decrease and the next asthma specific intervention trial, following
multiple reports correlating vitamin D with worse asthma out-
comes in human, animal and cell models, was not performed until
2009.
Before these vitamin D intervention trial, reports appeared
suggesting an increased risk of atopy with peanut oil þ vitamins A
and D. The first report of potentially increased risk of atopy with
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Table 3
Cross sectional studies of vitamin D status and asthma.
Population Age (years) Location Latitude Main findings Reference
18,224 adults. Not reported USA wide 28e48! N 25(OH)D was not correlated with allergic
sensitization. Risk of AR increased across
quartiles of 25(OH)D.
[181]
100 subjects with low 25(OH)D
(<25 nmol/L)
& 190 VDS subjects attending a weight
management centre.
10e73 Massachusetts, USA 41! N Themean BMI was 44.8 kg/m2 25(OH)Dwas not
correlated with prevalence of asthma or AR.
Low 25(OH)D was correlated with increased AD
compared to VDS.
[132]
616 asthmatic children. 6e14 Costa Rica
(city not specified)
~10! N 25(OH)D levels were inversely correlated with
total IgE, eosinophil count and hospitalization
for asthma in the past year.
[23]
7288 adults. 45 UK wide 51e58! N Non-linear correlation between 25(OH)D &
serum IgE, where both low and high 25(OH)D
were correlated with elevated IgE.
[83]
1024 asthmatic children. 7e11 USA wide 28e48! N Lower 25(OH)D levels were correlated with
increased ED visits and hospitalizations for
asthma.
[24]
100 asthmatic children. 4e10 Denver, USA 40! N 25(OH)D levels were inversely correlated with
total IgE, number of positive aeroallergen skin
tests and steroid usage but positively correlated
with FEV1 and FEV1/FVC.
[146]
54 asthmatic adults. 2e49 Denver, USA 40! N 25(OH)D level was inversely correlated with
total IgE, number of positive aeroallegen skin
tests and use of steroids but positively
correlated with FEV1 and FEV1/FVC.
[154]
75 asthmatic children. 5e11 Verona, Italy 45! N 25(OH)D correlated positively with FEV1, FVC
and ACT score.
[35,36]
Prospective study of 436 children, with
25(OH)D measured at 2y and
supplement usage assessed at age 1,
2 and 6e7 years.
6e7 Maastricht, The Netherlands 51! N 25(OH)D levels and vitamin D supplement use
in childhood were not correlated with lung
function
[42]
483 asthmatic children. <15 Doha, State of Qatar 25! N Lower 25(OH)D was correlated with more
allergic disease and elevated serum IgE.
[53]
4979 adults. >20 USA wide 28e48! N 25(OH)D < 25 nmol/L was positively correlated
with prevalence of allergies after adjusting for
age, gender, race, smoking, alcohol, and
educational status.
[58]
6857 adults & children. >6 USA wide 28e48! N 25(OH)D level was inversely correlated with
both current wheeze and asthma in adjusted
analysis. Among those with asthma, lower
25(OH)D was correlated with increased odds of
both ED visits and exacerbation in the past year.
[88]
21 subjects with asthma and 23
subjects with AD, or AR and atopic
sensitization.
Not reported Minnesota, USA 46! N Positive correlation between serum 25(OH)D
and positive pneumococcal antibody levels in
asthmatic subjects An inverse correlation was
observed in non-asthmatic patients.
[103]
435 adults. >18 Beijing, China 39! N 89% were VDD. After adjustment for
confounders, 25(OH)Dwas positively correlated
with FEV1, % FEV1, and FEV1/FVC. No correlation
between 25(OH)D and IgE.
[105]
372 4 year olds and 328 8 year olds from
the Prevention and Incidence of
Asthma andMite Allergy birth cohort
study.
4 and 8 Wageningen, Holland 51! N 25(OH)D level at age 4 was inversely with
asthma at age 4-8 but 25(OH)D level at age 8
was positively correlation with asthma.
[164]
22 moderate/severe asthmatics. 18e75 London, England 52! N 25(OH)D levels correlated strongly with CD4(þ)
Foxp3(þ) T-cell numbers.
[31]
16 atopic individuals (9 with asthma). 18e44 Baltimore, USA 39! N 25(OH)D and 1,25 were low in the airways.
After allergen challenge, 25(OH)D, 1,25D & LL-
37 were increased in BALF compared to saline
and correlated with each other. The increase in
25(OH)D and 1,25D correlated with the
magnitude of inflammation and increases in LL-
37.
[108]
994 participants (asthma prevalence
was 5.4%)
#65 South Korea
(city not specified)
~36! N With multivariate logistic regression, asthma
risk increased in proportion to an increased BMI
or abdominal subcutaneous adiposity.
However, no correlation was found with
visceral adiposity, serum adiponectin levels, or
25(OH)D levels
[150]
1024 asthmatic children 7e11 USA wide 28e48! N VDD was correlated with decreased lung
function (prebronchodilator FEV1) compared to
children with VDI or VDS.
[182]
Asthmatic out-patients (number of
subjects not specified)
Not reported San Juan, Puerto Rico 18! N 80% were VDD. 25(OH)D correlated positively
with ACT score but negatively with PEFR.
[188]
(continued on next page)
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Table 3 (continued )
Population Age (years) Location Latitude Main findings Reference
121 predominantly African-American
urban, preschool asthmatic children.
2e6 Baltimore, USA 38! N 23% were VDD, 31% were VDI. There was a
modest, statistically significant inverse
correlation between 25(OH)D levels and total
IgE.
[21]
15,212 individuals. >19 South Korea
(city not specified)
~36! N After adjusting for potential confounders,
25(OH)D levels were significantly lower in AD
than in those without this diagnosis. Compared
with VDI, VDD increased the odds of AD. There
was no relationship between 25(OH)D and
asthma, allergic rhinitis, or IgE sensitization.
[34]
Secondary analyses of 2 cohorts: 6,487
children from NHANES & 226
asthmatic children enrolled in study
of asthma control.
12e20 USA wide 28e48! N 25(OH)D level showed either no relation or
minor contradictory correlations with asthma
severity, treatment requirements, spirometry
and atopy/inflammation. 25(OH)D did not differ
between asthmatics and non-asthmatics
[61]
1,115 children. 9e10 Toyama, Japan 37! N 60% were VDI. After adjustment for
confounders, no relationship between 25(OH)D
and asthma, rhinoconjunctivitis, or eczema.
[84]
280 adult asthmatics. 45.0 ± 13.8 Mainz, Germany 50! N 67% were VDD. 25(OH)D levels were related to
asthma severity and control. The frequency of
VDI or VDD was significantly higher in patients
with severe or uncontrolled asthma and was
correlated with a lower FEV1, higher eNO and
higher BMI.
[94]
125 asthmatic children. 6e18 Bangkok, Thailand 13! N VDD was present in 31, 17 and 13% of children
with uncontrolled, partly controlled and
controlled asthma. However, there was no
significant difference in pulmonary function,
asthma exacerbation, ICS dose, anti-
inflammatory drugs, or ED visit or
hospitalization between different vitamin D
statuses.
[96]
121 asthmatic adults. 48 ± 16 Costa Rica
(city not specified)
~10! N VDI was correlated with a higher risk of severe
asthma. High 25(OH)D levels were inversely
correlated with risk of hospitalization or ED
visit during the last year. Although there
appeared to be a direct relationship between
25(OH)D and FEV1, it did not reach statistical
significance. No relationship between 25(OH)D
levels and some allergy markers.
[122]
2478 non-asthmatic, older adults. "55 Singapore 1! N Adjusted multiple regression models dietary
fish intake at least thrice weekly was correlated
with FEV1. No significant as with vitamin D
supplements was observed.
[127]
1833 children (rates of asthma, allergic
rhinitis and wheezing were 38.5%,
34.8% and 35.7%)
<16 Doha, Qatar 25! N VDD prevalence was significantly higher in
children with wheezing, AR, and asthma than in
healthy children. VDD was a significant
correlate for asthma, AR and wheezing.
[14]
1134 asthmatic children. 14.8 Lima and Tumbes, Peru 3.6e12! S In stratified analyses of multivariable logistic
regression, the correlation between lower
25(OH)D and asthma was limited to children
with atopy. No correlations between 25(OH)D
and eNO, total serum IgE and pulmonary
function.
[32]
308,000 adults. 6.9% (n ¼ 21,237), had
physician diagnosed asthma.
22e50 Tel Aviv, Israel 32! N No correlation between 25(OH)D and asthma
incidence. VDD was correlated with a 25%
greater risk of asthma exacerbation compared
to VDS independent of BMI and smoking.
[40]
32 asthmatic patients during severe
exacerbation
47.5 ± 15 Sichuan, China 30! N Compared to VDS, VDD was correlated with
lower FEV1 and SOD, increased ROS release,
increased DNA damage, increased TNF-a, OGG1
and NFkB expression and NFkB
phosphorylation.
[100]
760 adults with self reported asthma 19e55 Trondheim, Norway 63! N 44% were VDD but VDD was was not correlated
with airway obstruction except in asthmatic
men without allergic rhinitis.
[102]
1213 children. 6e12 Canada wide 50e70! N Children with either VDD & VDS were more
likely to report current wheeze and ever asthma
in comparison to VDI. The rate of increase in %
predicted FEV1 & FVC with age was greatest in
the VDI group.
[128]
92 adult asthmatics. 24e85 New Mexico, USA 31! N VDSwas significantly correlated with decreased
total and severe asthma exacerbations, and ER
visits.
[142]
2815 children 10 Germany (4 separate cities) 48e51! N There was no association between 25(OH)D and
either asthma or AR.
[169]
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vitamin D supplementation came in 1993. Peanut oil used for the
pharmacological preparation of vitamin D to prevent peanut
sensitization was associated with a markedly increased risk of
sensitization to allergen (OR ¼ 9.0; p < 0:003) compared to the
supplement without allergen [44]. Later trials of supplementation
with vitamins A and D dissolved in peanut oil and particularly
when dissolved in water demonstrated increased adverse allergic
outcomes, including asthma [45,97,98]. The preparations used
contained a combination of peanut oil as well as vitamins A and D,
and therefore it is difficult to speculate on the individual
contributions.
Since a call to action for vitamin D intervention trials in asthma
in 2009 [47], several small trials have been published:
Majak et al. conducted a double-blind, randomized, placebo-
controlled trial (DBRCT) to assess specific immunotherapy (SIT) in
combination with ICS (prednisone 20 mg daily) þ either placebo or
vitamin D3 (1000 IU/week). This was a one-year trial at high lati-
tude (51# N) and enrolled 54 asthmatic children allergic to house
dustmites on SIT. Early administration of ICS prevented the benefits
of SIT. However, the addition of low dose vitamin D3 (equivalent to
143 IU/day) preserved the benefits of SIT, despite concomitant ICS
use. Indeed, all negative clinical- and immunological-effects of
prednisone were prevented by administration of low dose vitamin
D3 [111]. For more detail on the potential of vitamin D as an adjunct
to anti-inflammatory therapy in asthma, see section 3.2.6 in part-
one of this review.
Urashima et al. conducted a DBRCT to assess the effectiveness of
vitamin D3 (2000 IU/d) vs. placebo in reducing influenza A inci-
dence in 334 Japanese school children. This four-month study
included physician diagnosed asthma exacerbations as a secondary
outcome. Although an 83% reduction in asthma attacks with
vitamin D was observed (RR: 0.17; 95% CI: 0.04, 0.73; p ¼ 0.006),
Table 3 (continued )
Population Age (years) Location Latitude Main findings Reference
1315 children. 5e18 Taoyuan, Taiwan 25# N 51% and 90.3% were VDD and VDI. After
adjusting for potential confounders. Serum
25(OH)D was not correlated with asthma,
rhinitis, eczema, atopy, or total serum IgE.
[184,185]
Abbreviations: 25(OH)D ¼ 25-hydroxyvitamin D; ACT ¼ asthma control test; AD ¼ atopic dermatitis; AR ¼ allergic rhinitis; ASM ¼ airway smooth muscle;
BALF ¼ bronchoalveolar lavage fluid; DBRCT ¼ double-blind, randomized, controlled trial; ED ¼ emergency department; ED ¼ emergency department; eNO ¼ exhaled nitric
oxide; FEV1 ¼ forced expiratory volume in 1 s; FVC ¼ forced vital capacity; ICS ¼ inhaled corticosteroid; IgE ¼ Immunoglobulin E; LL-37 ¼ the C-terminal part cathelicidn;
OCS ¼ oral corticosteroid; OGG-1 ¼ 8-Oxoguanine-DNA glycosylase; PEFR ¼ peak expiratory flow rate; ROS ¼ reactive oxygen species; SOD ¼ superoxide dismutases;
SR ¼ steroid resistant; VDD ¼ vitamin D deficiency; VDI ¼ vitamin D insufficiency; VDS ¼ vitamin D sufficiency.
Table 4
Prospective studies of post-natal cohorts of vitamin D and asthma.
Population Age (years) Location Latitude Main findings Reference
5007 subjects born in 1966 assessed at age 31. 31 Finland wide 60e70# N Atopy, allergic rhinitis and asthma prevalence
at age 31 was higher in participants who had
received regular vitamin D supplementation
during the first year of life, even after adjusting
for multiple behavioral and social factors.
[82]
123 neonates followed for 6y. All children were
prescribed supplements containing 1000 IU
vitamin A and 400 IU vitamin D3 daily from 6
weeks to 24 months of age.
Neonates Umeå, Sweden 64# N High self reported vitamin D intake during their
first 10 months was significantly positively
correlated with atopic dermatitis and non-
significantly correlated with allergic rhinitis and
atopic asthma compared to low self reported
vitamin D intake.
[8]
Longitudinal study of 989 subjects at age 6;
1380 at age 14; 689 with data at both ages.
6 and 14 Perth, Australia 32# S 25(OH)D level was inversely correlated with
asthma and atopy at both age 6 and 14. 25(OH)
D level at age 6y was inversely correlated with
asthma, rhinoconjunctivitis and atopy
development at age 14.
[77]
Prospective study of >2259 children (4%
wheezers, 14% asthma, 8% flexural dermatitis).
Mean follow up was 5.7y.
9.8 and 15.5 Bristol, United
Kingdom
51# N 25(OH)D2 was inversely correlated with
flexural dermatitis and wheezing. 25(OH) D3
was positively correlated with flexural
dermatitis and wheezing. 25(OH)D2 was weakly
positively correlated with FEV1, and FVC but
25(OH)D3 was not correlated with lung
function.
[157]
Post hoc analysis of an RCT comparing daily
low-dose budesonide to intermittent high-
dose budesonide in 120 children with severe
intermittent wheezing (71% had diagnosed
asthma) participating in a 1-year multicenter
DB RCT.
1e4.5 USA wide 28e48#N VDD was correlated with non-white ethnicity
and tobacco exposure. 25(OH)D level at
randomization was not correlated with the rate
of exacerbations requiring OCS therapy over the
1-year trial. However, VDD participants had a
significantly higher mean rate of exacerbations
requiring OCS compared with non-VDD
participants.
[13]
Prospective study of 3727 adults followed for
10y.
30e60 Copenhagen,
Denmark
57# N No correlation of 25(OH)D with atopy or
asthma. Low 25(OH)D was correlation with
lower % predicted FEV1. Correlation between
high baseline 25(OH)D and adverse changes in
lung function.
[156]
Abbreviations: 25(OH)D ¼ 25-hydroxyvitamin D; DB ¼ double-blind; FEV1 ¼ forced expiratory volume in 1 s; FVC ¼ forced vital capacity; OCS ¼ oral corticosteroid;
RCT ¼ randomized, controlled trial; VDD ¼ vitamin D deficiency.
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Table 5
Vitamin D intervention studies in asthma.
Design Duration (weeks) Population Dose Age Location Latitude Main findings Reference
Pilot study Varied: weeks to
months
3 non-atopic asthmatic,
2 subjects with chronic
uriticaria and 6 subjects
with ragweed
allergy þ asthma
Up to 1,380,000 IU
vitamin n D2 bi-
weekly
Not
specified
USA Not
specified
Non-atopic asthmatics and subjects
with uriticaria showed little
improvement while subjects with
ragweed allergy showed varying but
obvious improvements
[137]
Pilot study Varied: weeks to
months
212 patients with
ragweed allergy þ
asthma
vitamin D2
(120,000-
300,000 IU/
day) ± pollen
injection.
Not
specified
USA Not
specified
In the viosterol only group, 82.4%
improved, while. 96.5% in the
viosterol þ pollen group improved
[136]
Acute, crossover DBRCT Acute administration 12 patients with
allergic bronchial
asthma
oral calcium þ
vitamin D2
Not
specified
Germany Not
specified
Within 60 min of application, a
statistically significant reduction of
airway resistance and intrathoracic gas
volume, as well as an increase of FEV1
and forced inspiratory volume in 1 s
(FIV1) was observed compared to
placebo
[161]
3 arm DBRCT to assess the effectiveness
of SIT þ steroid vs. SIT, steroid þ
vitamin D3 vs. SIT, steroid þ placebo
52 54 asthmatic children
allergic to house dust
mites on SIT.
1000 IU vitamin D3/
week
6e12 Lodz, Poland 52" N ICS prevented the clinical and
immunological benefits of SIT. The
addition of vitamin D preserved the
benefits of SIT, despite concomitant ICS
use
[111]
DBRCT to assess the effectiveness of
vitamin D in reducing influenza A
incidence
16 334 Japanese school
children
2000 IU vitamin
D3/d
8e12 Japan wide 34e45" N 42% reduction in influenza A in vitamin
D group compared to placebo. In
asthmatics, this was associated with an
83% in asthma attacks
[160]
DBRCT ICS þ vitamin D3 vs. ICS þ
placebo
26 48 children with newly
diagnosed asthma
500 IU vitamin D3/d 5e18 Lodz, Poland 52" N Significantly lower risk of asthma
exacerbation in the vitamin D group. No
difference in serum 25(OH)D and ATAQ
scores
[112]
DBRCT to examine whether increased
25(OH)D levels either through
seasonal variations or
supplementation affect asthma
52 20 children with
chronic persistent
asthma
1000 IU vitamin
D3/d
6e17 Creighton, USA 42" N At baseline, 95% were VDI. Vitamin D
supplementation did not affect ACT
score or FEV1. However, children were
well controlled at baseline. Pooled data
on all 25(OH)D measurements and
corresponding ACT scores revealed a
significant positive correlation
[104]
DBRCT standard treatment þ vitamin D
or placebo
26 100 childhood
asthmatics
60,000 IU vitamin
D3 /month
Not
specified
New Delhi, India 28" N Significantly lower risk of asthma
exacerbation, steroid requirement and
ED visits in the vitamin D group
accompanied by significantly increased
PEFR
[183]
ICS or ICS plus LABA þ vitamin D or
placebo
24 130 asthmatics. 100,00 IU bolus IM
plus 50,000 IU
orally weekly
10e50 Tehran, Iran 36" N % FEV1 improved in both groups but to a
significantly greater degree in the
vitamin D group at 24 weeks
[6]
3 arm RCT of SCIT alone vs. SCIT þ
vitamin D vs. pharmacotherapy
alone
52 50 childhood
asthmatics sensitized to
house dust mite
650 IU vitamin D3/
day
5e15 Istanbul, Turkey. 41" N Asthma symptoms were lower in both
SCIT groups compared to
pharmacotherapy alone. However the
vitamin D supplemented group had
greater improvements
[12]
DBRCT of mild asthmatics currently not
receiving anti-inflammatory therapy
and with VDD/VDI
6 39 children 14,000 IU/week 6e18 Haifa, Israel 33" N No change in IgE, eosinophil count, hs-
CRP, FeNO levels, PC20- FEV1 or exhaled
breath condensate cytokines (IL-4, IL-5,
IL-10, IL-17, and IFN-g) between the
groups
[11]
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DBRCT of ICSþ vitamin D or ICS placebo 28 408 adults with
symptomatic asthma
and VDI
100,000 IU vitamin
D3 followed by
4000 IU/day
40 ± 13 USA wide 28e48"N Vitamin D supplementation had no
significant effect on the overall rate of
first treatment failure or exacerbation.
Significant reductions in exacerbations
and the rate of first treatment failure in
the 82% subjects who reached VDS
[30]
Unblinded, uncontrolled pilot 12 28 elderly asthmatics 2000 IU vitamin D3/
day
>65y Philadelphia, USA 40" N Mean 25(OH)D increased by 24 nmol/L.
There was no correlation between
25(OH)D and ICS dose. Vitamin D was
significantly lower in subjects with
uncontrolled asthma. In uncontrolled
asthma, ACT scores increased
significantly at the end of the study but
spirometry did not change
[39]
Randomly divided into vitamin D
supplementation or no
supplementation
Day 1 and 4 post
exacerbation.
16 VDD asthmatic
patients with severe
asthma exacerbation
were treated with
80 mg/day of
methylprednisolone for
7 days.
7.5 mg vitamin of
D3 IM.
45 ± 15 Sichuan, China. 30" N Supplemental vitamin D3 significantly
increased the rate of %FEV1
improvement and decreased airway
epithelial ROS as well as DNA damage
[100]
Open label, randomized trial of usual
care vs. usual care þ vitamin D
14 48 mild to moderate
persistent adult
asthmatics
? Not
specified
Porur, India. 13" N % FEV1 improved in both groups, but to
a greater extent in the vitamin D group
[125]
Proof-of-concept DBRCT of 1,25 as
adjunct to prednisolone
4 24 severe SR asthmatics 0.25 mg1,25D twice
daily
Not
specified
London, England 52" N No significant difference in % FEV1
between 1,25 and placebo. Within
group comparison of OCS þ1,25 or
placebo revealed a modest but
significant improvement in absolute
and predicted FEV1 with 1,25D. There
was a trend for a positive correlation
between baseline 25(OH)D and change
in predicted lung function following
OCS. Following prednisolone, there was
a greater improvement in % FEV1in VDS
compared to VDI.
[126]
DBRCT 9 44 patients with
nonatopic asthma with
neutrophilic and/or
eosinophilic airway
inflammation.
400,000 IU vitamin
D3 bolus
Not
specified
Leeuwarden, The
Netherlands
52" N Vitamin D did not significantly affect
sputum neutrophils or eosinophils
compared with placebo. However, sub
group analysis of subjects with airway
eosinophilia revealed that eosinophils
significantly decreased by 30% after
vitamin D compared with a 12%
increase in the placebo group. Vitamin
D treatment also resulted in slightly
better ACQ scores
[43]
Abbreviations; ACQ ¼ asthma control questionnaire; ACT ¼ asthma control test; ATAQ ¼ asthma therapy assessment questionnaire; DB ¼ double-blind; ED ¼ emergency department; FeNO ¼ fractional exhaled nitric oxide;
FEV1¼ forced expiratory volume in 1 s; hs-CRP¼ high sensitivity C reactive protein; ICS¼ inhaled corticosteroid; IFN-g¼ gamma interferon. IgE¼ immunoglobulin E; IL¼ interleukin; IU¼ international unit; LABA¼ long-acting
b-agonist; OCS ¼ oral corticosteroid; PC20- FEV1 ¼ provocation dose of methacholine require to induce a 20% drop in FEV1; PEFR ¼ peak expiratory flow rate; RCT ¼ randomized, placebo controlled trial; SCIT ¼ subcutaneous
immunotherapy; SIT ¼ specific immunotherapy; VDI ¼ vitamin D insufficiency; VDS ¼ vitamin D sufficiency; VDS ¼ vitamin D sufficiency.
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only 26% (n ¼ 110) of the sample had physician diagnosed asthma.
Additionally there was no assessment of 25(OH)D status or asthma
severity at any stage [160].
Following up on their preliminary work, Majak et al. conducted
a small, DBRCT of ICS vs. ICS þ vitamin D (500 IU/d). This was a 6
month trial conducted at high latitude (51# N) and enrolled 48
children with newly diagnosed asthma. There was a significant
increase in asthma exacerbations in the placebo group (OR, 8.6; 95%
CI, 2.1e34.6). However, the difference in serum 25(OH)D and
asthma therapy assessment questionnaire (ATAQ) scores between
the intervention and placebo group was very small and neither
reached statistical significance [112].
Retrospective, secondary analysis of pooled data obtained from
previously published DBRCTs on 36 asthmatic children undergoing
allergen immunotherapy revealed that higher serum 25(OH)D was
associated with a more significant reduction in asthma symptoms
and steroid use as well as higher TGF-a production and Foxp3 in-
duction [113].
Lewis et al. conducted a 1 year DBRCT to examine whether
increased 25(OH)D levels e either through seasonal variation or
supplementation - could affect asthma. In this one year study of 20
children with chronic persistent asthma, half were given 1000 IU
vitamin D3/d while the other half were given placebo and seasonal
variation in 25(OH)D was observed. 19 of the 20 enrolled children
were VDI at baseline. Although, vitamin D supplementation did not
affect ACT score or FEV1, all children were well controlled at base-
line. Further, pooled data on all 25(OH)D measurements and cor-
responding ACT scores revealed a significant positive correlation
(r ¼ 0.25, p < 0.05) [104].
Yadav &Mittal conducted a DBRCT to assess the effectiveness of
vitamin D3 (60,000 IU/month) vs. placebo in improving asthma
parameters. Compared to the placebo group, the vitamin D group
experienced reduced exacerbations (p ¼ 0.011) and steroid re-
quirements (p¼ 0.013) and increased expiratory flow rate, however
there was no report of 25(OH)D levels. The authors concluded:
‘Vitamin D has a definite role in the management of moderate to
severe persistent bronchial asthma as an adjunct to standard
treatment’ [183].
Arshi et al. conducted a 3 arm randomized trial of ICS vs. ICS plus
long-acting b-agonist (LABA) þ vitamin D3 vs. ICS plus LABA þ
placebo. This 24 week trial included asthmatics aged 10e50y and
the vitamin D dose was 100,00 IU bolus intramuscularly (IM) plus
50,000 IU orally weekly. Although, percentage predicted FEV1
improved in both groups, the improvement was significantly
greater in the vitamin D group at 24 weeks (p < 0.001) [6].
Baris et al. conducted a 3 arm, randomized trial of subcutaneous
immunotherapy (SCIT) alone (n ¼ 15), or with vitamin D3 supple-
mentation (650 IU/day; n¼ 17), or pharmacotherapy alone (n¼ 18).
Although both SCIT groups fared better than pharmacotherapy
alone at the end of 1 year, some favorable outcomes in the vitamin
D group were noted including better asthma controls as indicated
by corticosteroid treatment discontinuation in a greater percentage
of patients (p ¼ 0.02) [12].
Bar Yoseph et al. conducted a DBRCT of vitamin D supplemen-
tation (14,000 IU/week) vs. placebo for 6 weeks in asthmatic chil-
dren. There was no change in IgE, eosinophil count, high sensitivity
C reactive protein, fraction of exhaled nitric oxide levels or provo-
cation dose of methacholine require to induce a 20% drop in FEV1
between he vitamin D or placebo groups. Exhaled breath conden-
sate cytokines, including IL4, IL5, IL10, IL17, and interferon gamma
changed in both groups but there was no difference [11].
Castro et al. reported findings from the large Vitamin D Add-on
Therapy Enhances Corticosteroid Responsiveness in Asthma
(VIDA). Compared to placebo, a baseline 100,000 IU vitamin D3
bolus followed by 4000 IU daily for 28 weeks had no significant
effect on the overall rate of first treatment failure or exacerbation in
patients with asthma and VDI. However, at 28 weeks, there was a
significant difference in cumulative ciclesonide (a glucocorticoid)
dosing between the vitamin D and placebo groups (111.3 vs.
126.2 mg/day; p ¼ 0.02). Additionally, in the 82% of the vitamin D
supplementation group who reached VDS, there were significant
reductions in exacerbations and the rate of first treatment failure
[30]. Due to the baseline bolus dose and the moderate-high daily
dose, it was surprising that 18% of the vitamin D group did not reach
VDS, which may have affected the results. This may be due to the
obese nature of the cohort (mean BMI ¼ 32 kg/m2) or malabsorp-
tion, metabolism, or compliance issues with vitamin D.
Columbo et al. conducted an unblinded, uncontrolled pilot study
to assess the potential effect of vitamin D in elderly asthmatics. This
12 week study included 28 elderly asthmatics (>65y) adjunctly
treated with 2000 IU vitamin D3 daily. There was no association
between 25(OH)D and ICS dose or spirometric values. However,
25OH)D was significantly lower in subjects with uncontrolled
asthma and in uncontrolled asthma, ACT scores increased signifi-
cantly at the end of the study (p < 0.04).
Lan et al. conducted an unblinded pilot study to assess the acute
effects of 80 mg/day of methylprednisolone alone vs. combined
with 7.5 mg intramuscular vitamin D3 injection in vitamin D defi-
cient adults (in this study: <75 nmol/L) with severe asthma exac-
erbation. Vitamin D3 injections were given on day 1 and day 4. The
supplemental vitamin D3 significantly increased the rate of %FEV1
improvement and decreased reactive oxygen species aswell as DNA
damage compared tomonotherapywithmethylprednisolone [100].
Nageswari et al. conducted an open labeled, RCT of usual care
(budesonide and formoterol) vs. usual care þ vitamin D3 (1000 IU/
day). Although this trial was short (90 days) and included a small
cohort (n¼ 48), an increase in % predicted FEV1 was observed in the
usual care þ vitamin D group compared to the usual care only
group [125].
Nanzer et al. conducted a proof-of-concept DBRCT of 1,25D as
adjunct to prednisolone in 24 severe SR asthmatics. 0.25 mg 1,25D
was administered twice daily to the 1,25D group (n¼ 13). Although
there was no significant difference in %FEV1, a within-group com-
parison showing the change in lung function during the initial
screening in response to 2-week oral prednisolone vs. the response
to an identical course of prednisolone plus either placebo or 1,25D
revealed a modest but significant improvement in absolute and
predicted FEV1 with 1,25D compared to placebo (p ¼ 0.03). There
was no observed benefit in patients randomized to receive 1,25D
before the second course of prednisolone, suggesting that 1,25D
alone had no effect on lung function. A trend for a positive corre-
lation between baseline 25(OH)D and change in predicted lung
function following prednisolone (r ¼ 0.56, p ¼ 0.08) was observed.
Additionally, following prednisolone, there was a greater
improvement in % FEV1 in VDS compared to VDI subjects (p ¼ 0.03)
[126].
de Groot et al. conducted a DBRCT comparing a large bolus of
vitamin D3 (400,000 IU) to placebo. On a group level, there was no
significantly effect on sputum neutrophils or eosinophils with
vitamin D or placebo. However, subgroup analysis of subjects with
airway eosinophilia at baseline revealed that vitamin D signifi-
cantly decreased sputum eosinophils from a median of 41%e11.8%
compared to an increase from 51.8% to 63.3% in patients receiving
placebo (p ¼ 0.034). Vitamin D treatment also resulted in slightly
better Asthma Control Questionnaire scores (p ¼ 0.08) [43].
Although some of these interventional trials suggest a benefit of
vitamin D repletion, they are limited by small sample sizes, short
duration and potentially inadequate vitamin D dose. Nevertheless,
a recent systematic review and meta-analysis in paediatric asth-
matics noted a statistically significant reduction in asthma
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exacerbation with vitamin D supplementation (RR 0.41, CI
0.27e0.63) [134]. However, the need for adequately powered trials
utilizing adequate vitamin D dosing persists.
3.2. Why is data from human studies inconsistent?
The majority of existing epidemiologic and observational data
suggest that vitamin D intake and/or status may be of importance
in asthmatic disease. However, not all studies are in agreement
with some studies demonstrating no benefit from increased
vitamin D intake and/or status, while other reports suggest inferior
asthmatic outcomes associated with higher vitamin D. Vitamin D
represents a unique nutrient with many complexities. Although
some studies directly measure vitamin D status, other studies re-
cord vitamin D intake through food frequency questionnaires,
which can be a poor predictor of both vitamin D intake and 25(OH)
D status. Unlike other nutrients, the major source of vitamin D for
most people is not through diet, but from exposure to UV-B.
Therefore vitamin D status displays marked variation depending
on local weather conditions and individual sun behaviors e.g.
sunscreen use, time indoors etc. Most studies assess sun habits and
vitamin D status or intake at a single time point only. Human
behavior and season are variables, which change often and can
influence both asthma and vitamin D outcomes. Therefore epide-
miologic and observational studies are limited regarding asthma
and vitamin D.
Well designed, long term prospective and interventional studies
regarding vitamin D and asthmatic disease can providemore robust
evidence. To date there is a lack of these studies in asthma
(reviewed in Tables 4 and 5 respectively). However, again the re-
sults of existing prospective studies are conflicting. These pro-
spective studies have relied on a single measurement of vitamin D
status or intake with asthmatic outcomes assessed up to 31 years
later. Despite efforts to control for relevant, non-vitamin D con-
founders, it is impossible to discount variables other than vitamin D
contributing to the observations. Similarly, vitamin D intervention
studies to date provide inconsistent results. There have been 17
vitamin D intervention trials in asthma to date (Table 5). These
intervention trials differed in terms of trial design, vitamin D
dosing, outcome measures and trial duration, which may help
explain the inconsistencies.
4. Conclusions
4.1. What is the optimal vitamin D intakes and serum 25(OH) level
for asthma?
The recommendations for optimal vitamin D intake and serum
25(OH)D levels are controversial. The 2010 IOM report suggests a
recommended daily allowance of 600 IU for healthy subjects aged
>1y and a target serum 25(OH)D of >50 nmol/L [139]. However this
report was based almost exclusively on skeletal considerations and
has been criticized by experts in the vitamin D field [69,167]. Some
reports observed a plateau effect of serum 25(OH)D at 50 nmol/L
regarding exacerbations in asthmatics [13]. However, others sug-
gest a serum 25(OH)D level >100 nmol/L may be required for
optimal immunological and respiratory outcomes [17,76,78,79,166].
Conversely, both high and low 25(OH)D levels have been associated
with adverse outcomes in terms of increased aeroallergen sensiti-
zation [140], elevated IgE levels [83], and adverse changes in lung
function [156] raising the possibility that an optimal level of 25(OH)
D exists regarding asthma and that levels above or below are
detrimental.
It has been argued that in populations with limited sun expo-
sure that the current vitamin D recommendations are inadequate
for non-skeletal effects, and that intakes !2000 IU/day may be
required [74,76]. For example, a 500 IU supplement of vitamin D3
daily for 6 months was insufficient to increase serum 25(OH)D in
asthmatic children at 51" N [113]. In asthmatic children treated
with 1000 IU for 12 months only 50% reached vitamin D sufficiency
defined as >75 nmol/L [104]. Indeed, the Endocrine Society rec-
ommended vitamin D supplements of up to 4000 IU/day for adults
[76].
UV-B is the major source of vitamin D for most people, even at
high latitude [74] but with lifestyle changes and concerns about sun
damage, sun exposure has decreased contributing to widespread
VDI. However, achievable sunlight exposure may not be sufficient
for adequate 25(OH)D levels, particularly in urban and/or heavily
pigmented subjects [21]. Because vitamin D is naturally found in
few foods (mainly oily fish) and few food products are fortified
adequately (mainly dairy and cereal products), it is difficult to
achieve an adequate vitamin D status through diet al.one. Indeed,
dietary intake of vitamin D is typically inadequate [18], including
among asthmatic cohorts [25]. Further, a randomized controlled
trial demonstrated that diet was inadequate to achieve sufficient
serum 25(OH)D [41].
Although cod liver oil contains vitamin D3, its use has been
associated with increased asthma incidence [81,110,129] possibly
due to its high vitamin D content [27] and therefore may not
represent a suitable vehicle to increase vitamin D intake and serum
25(OH)D. Additionally, vitamin D2 is not as effective as vitamin D3
in maintaining serum 25(OH) levels [159].
4.2. Future recommendations
Despite, recent widespread publicity, vitamin D deficiency re-
mains highly prevalent throughout the world [74]. Here we have
presented human observational and interventional data regarding
vitamin D and asthma. Despite the recent advances in our under-
standing of the vitamin D pathway and its potential implications for
allergic and immune disorders such as asthma, many questions
remain:
# Is widespread vitamin D supplementation detrimental in
asthma as initially hypothesized or beneficial as mechanistic
and observational work suggest?
# Has vitamin D replacement therapy a role as an adjunct to anti-
inflammatory therapy or immunotherapy in asthma?
# Is the effect of vitamin D supplementation limited to a specific
asthma phenotype/endotype? And if so, which one?
# When is the therapeutic age range to exploit the potential
benefits of vitamin D supplementation in asthma?
# Should 25(OH)D be routinely measured in asthma?
# What is the desired serum 25(OH)D level for a potential thera-
peutic effect in asthma?
# What is the best strategy to achieve this desired serum 25(OH)D
level?
# Does peri-natal vitamin D supplementation reduce the risk of
developing asthma? The focus of the current manuscript was to
review existing human evidence that vitamin D may be of
importance in asthmatic disease. We have not comprehensively
reviewed studies of perinatal studies of vitamin D status or
intake. Existing trials in this area are inconsistent, probably
owing to important differences in study design for example
measuring vitamin D status versus reported vitamin D intake.
Additionally vitamin D levels are known to fluctuate over time
and are rapidly and significantly altered by modifiable human
behaviors such as location, sun behaviors and supplement use.
Therefore, the importance of a single vitamin D assessment in
early childhood or pregnancy is of debatable importance
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regarding future asthmatic outcomes. However manipulating
25(OH)D status holds promise for primary prevention of asthma
as recent reviews suggest [121,135].
! Is ultraviolet radiation a powerful immunomodulator in asth-
matic disease where 25(OHJ)D status merely reflects ultraviolet
exposure? For example acute ultraviolet exposure caused sys-
temic immunosuppression in the absence of increased 25(OH)D
in mice [64] This fascinating concept cannot be discounted
currently and is supported by several, recent animal studies
whereby ultraviolet exposure inhibited asthmatic disease
[117,118]. Relevant human evidence comes from inverse asso-
ciations with diverse respiratory tract symptoms [155], RSV
incidence [172,186] and risk of invasive pneumococcal disease
associated with UV-B (White et al., 2009). We briefly presented
human evidence suggesting a benefit of sunlight in asthmatic
disease above in section 3.1.2
New therapeutic options for wheezing disorders, and particu-
larly steroid resistant asthma are needed. Serum 25(OH)D level is a
novel and modifiable potential risk marker for severe asthma ex-
acerbations [55]. Taken together existing mechanistic and obser-
vational data support a role for vitamin D as an important factor in
asthma and infection. However, results from existing clinical trials
provide heterogeneous findings.
Vitamin D supplementation potentially represents a low-cost,
low-risk method to treat and prevent asthma and therefore
further exploration of the effect of vitamin D supplementation is
encouraged. Future trials should utilize adequate doses of vitamin
D3 preparations for interventions of sufficient duration. Appro-
priate trial duration appears likely to be >12 months considering
the half life of 25(OH)D is approximately 2e3 weeks [75] as well as
the natural seasonal variation in asthma and infection. Additionally,
because reported vitamin D intake and sun exposure are unreliable,
25(OH)D should be measured, preferably on more than one occa-
sion. This will also help determine optimal 25(OH)D levels and
decrease risk of vitamin D toxicity (VDT). VDT is rare and has most
reports of VDT have resulted from industrial accidents [4]. Never-
theless supraphysiological 25(OH)D levels (>375 nmol/L), which
are a possibility with extended use of inappropriately high doses of
vitamin D ("10,000 IU/d), can cause hypercalcemia and increased
risk of falls [144].
The data reviewed herein suggest that supplementation with
moderate doses (e.g. 1000 IU/d) of vitamin D3 may be appropriate
for maintenance of bone health in asthmatics, particularly steroid
users. However, existing data does not yet definitively support a
role for supplemental vitamin D therapy as a adjunct strategy in
asthmatic disease. Despite limited evidence, an adverse effect of
widespread vitamin D supplementation can not be discounted and
therefore caution is advised until more definitive evidence is
available.
Childhood asthma and steroid resistant asthma are key under-
explored areas where vitamin D based interventions may provide
benefit. Only the results of well-designed, clinical trials can elude as
to effects of vitamin D therapy asthma. Indeed there has been a call
to action for well-designed intervention trials of vitamin D sup-
plementation to assess its role in preventing and treating asthma
[47]. Ongoing longitudinal studies and clinical trials should help
ultimately answer some of the existing questions.
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